Your session is about to expire
← Back to Search
This trial is testing a combination of chemotherapy drugs with atezolizumab to see if it is more effective than chemotherapy alone in treating patients with stage III colon cancer. Atezolizumab is an immunotherapy drug that may help the body's immune system attack the cancer.
- Stage III Colon Cancer
- Colorectal Cancer
- DNA Repair Disorder
- Lynch Syndrome
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Side effects dataFrom 2019 Phase 3 trial • 1225 Patients • NCT02008227
Awards & Highlights
Find a Location
Who is running the clinical trial?
- You do not have any ongoing autoimmune diseases such as colitis, inflammatory bowel disease, rheumatoid arthritis, or adrenal insufficiency.You do not have moderate or severe nerve damage in your arms or legs.You have never had a severe allergic reaction to certain types of medications called chimeric, human, or humanized antibodies.You are not allergic to any ingredients in the atezolizumab medication, including Chinese hamster ovary (CHO) cell products.
- Group 1: Arm II (combination chemotherapy)
- Group 2: Arm I (combination chemotherapy, atezolizumab)
- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Could you elaborate on Atezolizumab's previous research?
"At present, 923 clinical trials are underway to study the efficacy of Atezolizumab. Of those active studies, 266 are in Phase 3. Although a large number of these trials for Atezolizumab originate in Guangzhou, Guangdong, there are actually 42746 locations conducting research on this treatment worldwide."
Atezolizumab is most commonly used to target which type of cells?
"Atezolizumab, which is most often used as a treatment for macrocytic anemia, can also be taken to manage metastatic ureter urothelial carcinoma, bladder cancer, and other conditions."
Do people who take Atezolizumab experience many side effects?
"Atezolizumab has received a Phase 3 safety rating from our analysts at Power. What this means is that while there are still some unknowns surrounding the efficacy of the medication, it has undergone multiple rounds of testing with positive results for safety."
Are investigators still looking for more participants in this study?
"The clinical trial is still recruiting patients, as of today. This information can be found by looking at the posting date (9/12/2017) and last edit date (11/16/2022) on clinicaltrials.gov"
Who else is applying?
What state do they live in?
How old are they?
What site did they apply to?
What portion of applicants met pre-screening criteria?
How many prior treatments have patients received?
Why did patients apply to this trial?
Share this study with friends